Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry

We examined factors that may impact cabazitaxel treatment duration in a real-life setting in a compassionate use program, expanded access program, and prospective observational study in metastatic castration-resistant prostate cancer (mCRPC). Patients with mCRPC previously treated with docetaxel (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Zafar, Di Lorenzo, Giuseppe, Pichler, Angelika, De Giorgi, Ugo, Hitier, Simon, Ecstein-Fraisse, Evelyne, Ozatilgan, Ayse, Carles, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226228/
https://www.ncbi.nlm.nih.gov/pubmed/32316580
http://dx.doi.org/10.3390/cancers12040995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226228/
https://www.ncbi.nlm.nih.gov/pubmed/32316580
http://dx.doi.org/10.3390/cancers12040995

Ejemplares similares